Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2013 2
2014 1
2016 4
2017 1
2019 2
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Updating the OMERACT filter: implications for patient-reported outcomes.
Kirwan JR, Bartlett SJ, Beaton DE, Boers M, Bosworth A, Brooks PM, Choy E, de Wit M, Guillemin F, Hewlett S, Kvien TK, Landewé RB, Leong AL, Lyddiatt A, March L, May J, Montie PL, Nikaï E, Richards P, Voshaar MM, Smeets W, Strand V, Tugwell P, Gossec L. Kirwan JR, et al. Among authors: nikai e. J Rheumatol. 2014 May;41(5):1011-5. doi: 10.3899/jrheum.131312. Epub 2014 Mar 1. J Rheumatol. 2014. PMID: 24584919
Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations.
Blauvelt A, Griffiths CEM, Lebwohl M, Mrowietz U, Puig L, Ball S, Zhang L, Edson-Heredia E, Warner M, Zhu B, Lin CY, Nikaï E, Dey D, Mallbris L, Reich K. Blauvelt A, et al. Among authors: nikai e. Br J Dermatol. 2017 Aug;177(2):587-590. doi: 10.1111/bjd.15463. Epub 2017 Jul 3. Br J Dermatol. 2017. PMID: 28301048 Clinical Trial. No abstract available.
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M. Langley RGB, et al. Among authors: nikai e. Qual Life Res. 2020 Feb;29(2):369-380. doi: 10.1007/s11136-019-02296-5. Epub 2019 Oct 26. Qual Life Res. 2020. PMID: 31655974 Clinical Trial.
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, Zhu B, Edson-Heredia E, Carlier H, Lin CY, Goldblum O, Yosipovitch G. Kimball AB, et al. Among authors: nikai e. J Am Acad Dermatol. 2016 Dec;75(6):1156-1161. doi: 10.1016/j.jaad.2016.07.034. Epub 2016 Sep 27. J Am Acad Dermatol. 2016. PMID: 27692498 Clinical Trial.
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A. Strand V, et al. Among authors: nikai e. Arthritis Res Ther. 2009;11(6):R170. doi: 10.1186/ar2859. Epub 2009 Nov 12. Arthritis Res Ther. 2009. PMID: 19909548 Free PMC article. Clinical Trial.
13 results